Which has stronger valuation & earnings, LIVN or SOLV?

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.38 -$242.47M $1.95 43.75 Solventum $8.33B 1.83 $1.56B $8.16 10.79

Is LIVN or SOLV more profitable?

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Solventum 17.33% 23.51% 7.63%

Does the media refer more to LIVN or SOLV?

In the previous week, LivaNova had 1 more articles in the media than Solventum. MarketBeat recorded 10 mentions for LivaNova and 9 mentions for Solventum. LivaNova's average media sentiment score of 1.41 beat Solventum's score of 0.72 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, SNN or LIVN?

Smith & Nephew SNATS has higher revenue and earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.09 $625M N/A N/A LivaNova $1.39B 3.38 -$242.47M $1.95 43.75

Does the media prefer SNN or LIVN?

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 10 mentions for LivaNova. LivaNova's average media sentiment score of 1.41 beat Smith & Nephew SNATS's score of -0.18 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral LivaNova 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, LIVN or PEN?

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.38 -$242.47M $1.95 43.75 Penumbra $1.40B 9.10 $177.69M $4.07 79.64

Is LIVN or PEN more profitable?

Penumbra has a net margin of 10.67% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Penumbra 10.67% 10.50% 8.17%

Does the media refer more to LIVN or PEN?

In the previous week, LivaNova had 2 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for LivaNova and 8 mentions for Penumbra. LivaNova's average media sentiment score of 1.41 beat Penumbra's score of 0.73 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, LIVN or GKOS?

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.38 -$242.47M $1.95 43.75 Glaukos $507.44M 19.78 -$187.69M -$3.25 N/A

Is LIVN or GKOS more profitable?

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -30.68%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Glaukos -30.68% -6.37% -4.78%

Does the media refer more to LIVN or GKOS?

In the previous week, Glaukos had 18 more articles in the media than LivaNova. MarketBeat recorded 28 mentions for Glaukos and 10 mentions for LivaNova. LivaNova's average media sentiment score of 1.41 beat Glaukos' score of 0.74 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 10 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, LQDA or LIVN?

Liquidia has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 49.64 -$68.92M $0.14 631.29 LivaNova $1.39B 3.38 -$242.47M $1.95 43.75

Is LQDA or LIVN more profitable?

Liquidia has a net margin of 7.74% compared to LivaNova's net margin of 7.48%. Liquidia's return on equity of 46.82% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% LivaNova 7.48% 16.48% 7.59%

Does the media favor LQDA or LIVN?

In the previous week, Liquidia had 3 more articles in the media than LivaNova. MarketBeat recorded 13 mentions for Liquidia and 10 mentions for LivaNova. LivaNova's average media sentiment score of 1.41 beat Liquidia's score of 0.74 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Live Earnings Conference Call: LivaNova's Q2 2026 earnings call is happening now. Listen live.

LivaNova (LIVN) Competitors

$85.32 +2.86 (+3.47%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$86.39 +1.07 (+1.25%)

As of 08:03 AM Eastern

Compare

LIVN vs. SOLV, SNN, PEN, GKOS, and LQDA

Should you buy LivaNova stock or one of its competitors? MarketBeat compares LivaNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LivaNova include Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), Glaukos (GKOS), and Liquidia (LQDA).

How does LivaNova compare to Solventum?

LivaNova (NASDAQ:LIVN) and Solventum (NYSE:SOLV) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

LivaNova presently has a consensus price target of $81.38, suggesting a potential downside of 4.62%. Solventum has a consensus price target of $86.00, suggesting a potential downside of 2.32%. Given Solventum's higher possible upside, analysts clearly believe Solventum is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.38	-$242.47M	$1.95	43.75
Solventum	$8.33B	1.83	$1.56B	$8.16	10.79

LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Solventum has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

97.6% of LivaNova shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, LivaNova had 1 more articles in the media than Solventum. MarketBeat recorded 10 mentions for LivaNova and 9 mentions for Solventum. LivaNova's average media sentiment score of 1.41 beat Solventum's score of 0.72 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Solventum	17.33%	23.51%	7.63%

Summary

LivaNova beats Solventum on 9 of the 17 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Smith & Nephew SNATS currently has a consensus target price of $30.93, indicating a potential upside of 1.45%. LivaNova has a consensus target price of $81.38, indicating a potential downside of 4.62%. Given Smith & Nephew SNATS's higher probable upside, analysts clearly believe Smith & Nephew SNATS is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Smith & Nephew SNATS has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Smith & Nephew SNATS had 1 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Smith & Nephew SNATS and 10 mentions for LivaNova. LivaNova's average media sentiment score of 1.41 beat Smith & Nephew SNATS's score of -0.18 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
LivaNova	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.09	$625M	N/A	N/A
LivaNova	$1.39B	3.38	-$242.47M	$1.95	43.75

LivaNova has a net margin of 7.48% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.48% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
LivaNova	7.48%	16.48%	7.59%

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LivaNova beats Smith & Nephew SNATS on 10 of the 15 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

LivaNova (NASDAQ:LIVN) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, LivaNova had 2 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for LivaNova and 8 mentions for Penumbra. LivaNova's average media sentiment score of 1.41 beat Penumbra's score of 0.73 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Penumbra has a net margin of 10.67% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Penumbra	10.67%	10.50%	8.17%

LivaNova presently has a consensus target price of $81.38, suggesting a potential downside of 4.62%. Penumbra has a consensus target price of $367.07, suggesting a potential upside of 13.24%. Given Penumbra's higher probable upside, analysts plainly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Penumbra	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12

LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.38	-$242.47M	$1.95	43.75
Penumbra	$1.40B	9.10	$177.69M	$4.07	79.64

Summary

Penumbra beats LivaNova on 9 of the 17 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

LivaNova (NASDAQ:LIVN) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

LivaNova has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Glaukos has lower revenue, but higher earnings than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.38	-$242.47M	$1.95	43.75
Glaukos	$507.44M	19.78	-$187.69M	-$3.25	N/A

In the previous week, Glaukos had 18 more articles in the media than LivaNova. MarketBeat recorded 28 mentions for Glaukos and 10 mentions for LivaNova. LivaNova's average media sentiment score of 1.41 beat Glaukos' score of 0.74 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	10 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova presently has a consensus target price of $81.38, indicating a potential downside of 4.62%. Glaukos has a consensus target price of $177.33, indicating a potential upside of 4.19%. Given Glaukos' stronger consensus rating and higher probable upside, analysts plainly believe Glaukos is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -30.68%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Glaukos	-30.68%	-6.37%	-4.78%

97.6% of LivaNova shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

LivaNova beats Glaukos on 9 of the 17 factors compared between the two stocks.

How does LivaNova compare to Liquidia?

Liquidia (NASDAQ:LQDA) and LivaNova (NASDAQ:LIVN) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Liquidia has a net margin of 7.74% compared to LivaNova's net margin of 7.48%. Liquidia's return on equity of 46.82% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
LivaNova	7.48%	16.48%	7.59%

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Liquidia has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	49.64	-$68.92M	$0.14	631.29
LivaNova	$1.39B	3.38	-$242.47M	$1.95	43.75

Liquidia has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

In the previous week, Liquidia had 3 more articles in the media than LivaNova. MarketBeat recorded 13 mentions for Liquidia and 10 mentions for LivaNova. LivaNova's average media sentiment score of 1.41 beat Liquidia's score of 0.74 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia presently has a consensus price target of $86.18, indicating a potential downside of 2.49%. LivaNova has a consensus price target of $81.38, indicating a potential downside of 4.62%. Given Liquidia's stronger consensus rating and higher probable upside, equities analysts plainly believe Liquidia is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Liquidia beats LivaNova on 10 of the 17 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.53B	$5.78B	$6.83B	$12.77B
Dividend Yield	N/A	1.78%	2.60%	10.01%
P/E Ratio	43.75	23.44	279.15	25.53
Price / Sales	3.38	43.98	591.00	92.31
Price / Cash	17.05	32.60	72.11	49.39
Price / Book	3.88	6.13	13.02	6.11
Net Income	-$242.47M	$150.91M	$3.48B	$347.58M
7 Day Performance	4.78%	5.98%	3.39%	4.91%
1 Month Performance	2.03%	0.99%	-2.80%	-2.06%
1 Year Performance	100.23%	9.09%	73.07%	21.03%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.1932 of 5 stars	$85.32 +3.5%	$81.38 -4.6%	+99.5%	$4.53B	$1.39B	43.75	3,300	Positive News Earnings Report High Trading Volume
SOLV Solventum	2.9931 of 5 stars	$80.49 +3.2%	$81.91 +1.8%	+20.2%	$13.51B	$8.26B	9.86	20,000	Positive News
SNN Smith & Nephew SNATS	1.8287 of 5 stars	$31.14 +1.9%	$30.93 -0.7%	-1.0%	$12.92B	$6.16B	N/A	16,988	News Coverage Analyst Downgrade
PEN Penumbra	2.7561 of 5 stars	$319.46 +0.2%	$360.33 +12.8%	+34.7%	$12.54B	$1.40B	73.61	4,700	Earnings Report
GKOS Glaukos	1.8997 of 5 stars	$152.07 -1.0%	$154.85 +1.8%	+94.5%	$9.02B	$507.44M	N/A	1,094	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors